IRB Study Number 14-1222
Status Recruiting
Location Cleveland Clinic Main Campus
Institute Taussig Cancer Institute
Description
The objective of this tissue and body fluid procurement protocol is to obtain sufficient quantities of benign and neoplastic urothelium and bladder tissue to support our current and proposed translational research studies. We intend to collect bio-specimens until our clinical, pathological and molecular signature, target and biomarker discovery and validation studies can be sufficiently powered to produce meaningful results.
Inclusion Criteria
All patients entering clinical care at the Cleveland Clinic Foundation (CCF) with a known or suspected diagnosis of urothelial cancer (or other bladder cancer histologic type) or those who require removal of bladder organ or urothelial tissue (as a source of normal, non-neoplastic urothelium) will be considered as a potential source for these specimens and they will be considered for consent on this protocol to allow for collection of one or more of the above samples as appropriate.
Exclusion Criteria
none
